Golden Biotechnology Corporation (TPEX:4132)

Market Cap	2.71B -4.8%
Revenue (ttm)	44.58M -22.5%
Net Income	-314.93M
EPS	-1.96
Shares Out	162.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	978,134
Average Volume	780,092
Open	17.35
Previous Close	16.80
Day's Range	15.70 - 17.35
52-Week Range	9.98 - 36.30
Beta	0.52
RSI	40.50
Earnings Date	Apr 27, 2026

About Golden Biotechnology

Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and neurodegenerative diseases. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 122
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4132

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.